About Valneva SE
https://valneva.comValneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs.
CEO
Thomas Lingelbach
Compensation Summary
(Year )
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
NOVO HOLDINGS A/S
Shares:2.35M
Value:$24.32M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:2.29M
Value:$23.76M
GENERAL AMERICAN INVESTORS CO INC
Shares:354.36K
Value:$3.67M
Summary
Showing Top 3 of 20
About Valneva SE
https://valneva.comValneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $29.41M ▼ | $42.62M ▲ | $-44.35M ▼ | -150.82% ▼ | $-0.52 ▼ | $-37.8M ▼ |
| Q2-2025 | $48.33M ▼ | $35.08M ▲ | $-11.59M ▼ | -23.97% ▼ | $-0.15 ▼ | $-6.2M ▼ |
| Q1-2025 | $49.23M ▼ | $32.15M ▼ | $-9.23M ▲ | -18.75% ▲ | $-0.12 ▲ | $-1.78M ▲ |
| Q4-2024 | $52.94M ▲ | $46.59M ▲ | $-36.99M ▼ | -69.86% ▼ | $-0.52 ▼ | $-25.77M ▼ |
| Q3-2024 | $45.82M | $32.59M | $-9.24M | -20.16% | $-0.13 | $-7.22M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $161.31M ▲ | $472.63M ▼ | $286.19M ▼ | $186.43M ▲ |
| Q1-2025 | $152.99M ▼ | $482.24M ▼ | $306.99M ▼ | $175.25M ▼ |
| Q4-2024 | $168.27M ▲ | $500.03M ▼ | $318.78M ▲ | $181.25M ▼ |
| Q3-2024 | $156.34M ▲ | $516.61M ▲ | $299.14M ▼ | $217.47M ▲ |
| Q2-2024 | $131.41M | $466.57M | $300.29M | $166.28M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-11.59M ▼ | $-2.79M ▲ | $-681K ▲ | $14.88M ▲ | $8.32M ▲ | $-4.05M ▲ |
| Q1-2025 | $-9.23M ▲ | $-8.15M ▼ | $-961K ▼ | $-5.58M ▼ | $-15.28M ▼ | $-9.62M ▼ |
| Q4-2024 | $-36.99M ▼ | $9.53M ▲ | $4.69M ▲ | $-4.59M ▼ | $11.94M ▼ | $5.67M ▲ |
| Q3-2024 | $-9.24M ▲ | $-10.48M ▲ | $-15.38M ▼ | $51.86M ▲ | $24.92M ▲ | $-26.39M ▲ |
| Q2-2024 | $-24.93M | $-37.83M | $895K | $-9.13M | $-45.23M | $-37.48M |
CEO
Thomas Lingelbach
Compensation Summary
(Year )
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
NOVO HOLDINGS A/S
Shares:2.35M
Value:$24.32M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:2.29M
Value:$23.76M
GENERAL AMERICAN INVESTORS CO INC
Shares:354.36K
Value:$3.67M
Summary
Showing Top 3 of 20